North America Next-Generation Cancer Therapeutics Market Size, Share & Trends Analysis Report By Therapy Type (Targeted Therapy (Small Molecule Inhibitors), Immunotherapy Checkpoint Inhibitors (PD-1, PD-L1, CTLA-4) CAR-T Cell Therapy Cancer Vaccines, Gene Therapy, Cell Therapy (e.g., TILs, NK cells) ), By Cancer Type (Lung Cancer, Breast Cancer, Colorectal Cancer, Blood Cancers (Leukemia, Lymphoma, Myeloma) ), By Country (U.S., Canada) and Forecast, 2026-2034

North America Next-Generation Cancer Therapeutics Market Trends

Precision Oncology, Engineered Immunity, and Multi-Mechanism Treatment

Cancer therapeutics are moving toward biomarker-directed and engineered platforms rather than uniform cytotoxic treatment. In 2025, the FDA's CDER approved 46 novel drugs across therapeutic areas, while regulatory activity in oncology continued to include new targeted agents, ADCs, and expanded indications. In February 2026, zongertinib received an FDA decision only 44 days after filing; submitted trial data showed tumor-size reduction in 76% of previously untreated patients versus an expected 30–45% response under the cited standard of care.

Commercial adoption also demonstrates the scale achievable by advanced immuno-oncology platforms. KEYTRUDA generated USD 31.64 billion worldwide in 2025, including USD 18.83 billion in U.S. sales, while first-quarter 2026 KEYTRUDA revenue reached USD 7.91 billion, up 10% year over year. The shift toward combination regimens, subcutaneous formulations, tumor-specific biomarkers, ADC payload engineering, and one-time engineered-cell interventions is expanding treatment choice across dozens of approved indications.

North America Next-Generation Cancer Therapeutics Market Drivers

Expanding Precision-Oncology Eligibility and Regulatory Throughput

Greater biomarker testing and broader indications are increasing addressable patient pools. KEYTRUDA/KEYTRUDA QLEX generated USD 31.68 billion globally in 2025, 7% above 2024, while WELIREG increased 41% to USD 716 million and Lynparza alliance revenue increased 11% to USD 1.45 billion. In 2026, zongertinib's supporting data demonstrated a 76% tumor-size response among previously untreated patients compared with 30–45% cited for existing care, illustrating how clinically differentiated outcomes can accelerate uptake.

North America Next-Generation Cancer Therapeutics Market Restraints

Complex Manufacturing, Safety Management, and Treatment Infrastructure

Engineered therapies require specialized manufacturing, trained centers, monitoring, and patient-specific logistics that remain substantially more complicated than conventional oral medicines. CAR-T products historically operated under dedicated REMS because of cytokine-release syndrome and neurological toxicity risks; in June 2025 the FDA eliminated REMS requirements for currently approved BCMA- and CD19-directed autologous CAR-T therapies. Although this reduces administrative burden, treatment still involves sophisticated clinical infrastructure, while rare indications can represent only thousands of eligible patients; marginal zone lymphoma, for example, accounts for roughly 7% of B-cell non-Hodgkin lymphoma and approximately 7,460 new U.S. cases annually.

North America Next-Generation Cancer Therapeutics Market Opportunities

ADC Expansion and Combination Regimens Broaden Addressable Oncology Populations

ADCs and rational combinations are opening additional treatment lines across breast, lung, and hematologic malignancies. In February 2025, FDA approval of brentuximab vedotin with lenalidomide and rituximab was supported by a randomized trial involving 230 adults assigned 1:1 between treatment groups. By May 2026, FDA approvals included datopotamab deruxtecan for metastatic triple-negative breast cancer and two separate indications for trastuzumab deruxtecan in HER2-positive early-stage breast cancer, illustrating rapid expansion from late-stage to earlier-stage settings.

Challenges in North America Next-Generation Cancer Therapeutics Market

Balancing Clinical Differentiation with Access and Portfolio Concentration

Developers face increasingly demanding evidence requirements as multiple modalities compete for overlapping biomarker-defined populations. Commercial concentration can be substantial: KEYTRUDA produced USD 31.68 billion globally in 2025 and increased 7%, whereas newer WELIREG generated USD 716 million while expanding 41%. At the same time, advanced treatments must compete across oral targeted drugs, infused antibodies, ADCs, and engineered cells, creating pressure to demonstrate response durability, manageable toxicity, convenient administration, and superior economics rather than incremental efficacy alone.

North America Next-Generation Cancer Therapeutics Market Segmentation

The landscape is segmented by therapy type, cancer type, modality, route of administration, mechanism of action, and end-user. Therapy data show targeted therapy holding approximately 30.3% of the 2026 therapy-level total, followed by gene therapy at 26.0% and immunotherapy at 20.1%.

By Therapy Type

Targeted therapy is the largest category, increasing from USD 8,866.16 million in 2025 to USD 9,591.41 million in 2026 and USD 17,991.13 million by 2034 at 8.18% CAGR. It represents approximately 30.3% of the USD 31,705.09 million therapy-level total in 2026.

Targeted therapy is also the fastest-expanding listed therapy at 8.18% CAGR, narrowly ahead of ADCs at 8.12% and gene therapy at 7.97%. Immunotherapy reaches USD 11,224.36 million by 2034 at 7.36%, while RNA-based therapy reaches USD 2,939.60 million at 7.49%.

By Cancer Type

Segmentation covers 7 principal categories: lung, breast, colorectal, blood, prostate, brain, and pan-tumor cancers. These categories capture both high-incidence solid tumors and biomarker-defined populations, with pan-tumor approaches allowing one molecular alteration to support treatment across multiple tissue origins.

No cancer-type market values or CAGRs were supplied in the mandatory dataset; therefore, numerical size or CAGR allocations are not inferred. The analysis retains all 7 supplied categories without redistributing the USD 31,705.09 million therapy total.

By Modality

The modality framework comprises 2 primary groups—monotherapy and combination therapy—with 3 specified combination approaches: immunotherapy plus targeted drugs, chemotherapy plus ADCs, and mRNA plus checkpoint inhibitors.

No modality-level size or CAGR values were provided. Consequently, the USD 31,705.09 million 2026 therapy dataset and USD 58,059.76 million 2034 therapy projection are not artificially apportioned between the 2 modalities.

By Route of Administration

The market is classified across 4 routes: intravenous, oral, intratumoral/localized, and subcutaneous administration. These routes accommodate infused antibodies and cells, orally administered small molecules, localized agents, and increasingly convenient injectable formulations.

No route-specific market values or CAGRs were supplied. Accordingly, the 4 categories are assessed structurally without creating unsupported shares from the USD 31,705.09 million 2026 therapy total.

By Mechanism of Action

The framework contains 5 mechanisms: immune activation, oncogene targeting, DNA-damage response modulation, tumor-microenvironment modulation, and apoptosis induction. These mechanisms span established checkpoint blockade through increasingly precise molecular intervention.

Mechanism-level size and CAGR data were not provided. The 5 categories therefore remain qualitative classifications and are not assigned portions of the USD 58,059.76 million therapy-level 2034 projection.

By End-User

The end-user structure includes 4 settings: specialized cancer hospitals, academic and research institutes, ambulatory infusion centers, and homecare. Delivery requirements differ considerably between complex cell therapies and oral or subcutaneous treatments.

No end-user-specific size or CAGR figures were supplied. The 4 end-user groups are therefore retained without imposing unsupported numerical allocations on the 2026 or 2034 totals.

North America Next-Generation Cancer Therapeutics Market Counties Outlook

U.S.

The U.S. accounts for USD 22,540.30 million in 2026, approximately 71.2% of the North American country-level total, compared with USD 20,930.73 million in 2025. The country is projected to reach USD 40,772.07 million by 2034 at 7.69% CAGR, adding USD 18,231.77 million over the forecast period.

The U.S. contribution reflects substantial oncology commercialization and regulatory throughput. As one indicator of commercial penetration, KEYTRUDA generated USD 18.83 billion in U.S. sales during 2025, while FDA activity continued across targeted drugs, ADCs, immunotherapies, and engineered-cell products.

Canada

Canada is valued at USD 9,131.82 million in 2026, representing approximately 28.8% of the regional country-level total, compared with USD 8,466.36 million in 2025. It is projected to reach USD 16,727.86 million by 2034 at 7.86% CAGR.

Canada therefore expands slightly faster than the U.S., with a CAGR advantage of 0.17 percentage points. Its absolute increase of USD 7,596.04 million between 2026 and 2034 supports a continuing role for specialized hospitals, infusion infrastructure, precision medicines, and advanced biologic treatment pathways.

Top players in North America Next-Generation Cancer Therapeutics Market

1. Merck & Co., Inc.
2. Bristol Myers Squibb
3. Roche/Genentech
4. Johnson & Johnson
5. AstraZeneca
6. Pfizer
7. Novartis
8. Gilead Sciences
9. Eli Lilly and Company
10. Amgen
11. AbbVie
12. Regeneron Pharmaceuticals
13. Daiichi Sankyo
14. Moderna
15. BioNTech

Top Two Companies

• Merck & Co., Inc.— A precise percentage share of the defined North American market cannot be calculated from the supplied company data without conflating product revenue with market revenue. Merck nevertheless holds a leading competitive position through KEYTRUDA, which generated USD 31.68 billion worldwide in 2025, including USD 18.83 billion in the U.S. First-quarter 2026 KEYTRUDA sales reached USD 7.91 billion, up 10% year over year. Its position extends across checkpoint inhibition, combination regimens, earlier-stage disease, and additional oncology assets including WELIREG and Lynparza alliance revenue.
• Bristol Myers Squibb— A defensible percentage share cannot be derived from the mandatory tables because company-level revenues aligned precisely with the defined market boundary were not supplied. Bristol Myers Squibb remains strongly positioned through immuno-oncology and cell therapy, including checkpoint-based treatments and CAR-T platforms. Regulatory momentum remains relevant: in December 2025, FDA approved Breyanzi for marginal zone lymphoma after 2 or more prior systemic treatment lines, making it the first CAR-T therapy approved in the U.S. for that indication.

Recent Developments in the North America Next-Generation Cancer Therapeutics Market

• 2026: On May 27, FDA approved AbbVie's pivekimab sunirine-pvzy, a CD123-directed antibody and alkylating-agent conjugate, for adults with BPDCN.
• 2026: On May 22, FDA approved Daiichi Sankyo's datopotamab deruxtecan for unresectable or metastatic triple-negative breast cancer in specified patients.
• 2026: On May 15, FDA approved trastuzumab deruxtecan for 2 separate HER2-positive early-stage breast cancer indications.
• 2026: In February, the FDA approved zongertinib through its National Priority Voucher pilot after a 44-day review period; submitted data reported substantial tumor-size reduction in 76% of previously untreated patients.
• 2025: In December, the FDA approved Breyanzi as the first U.S. CAR-T treatment for marginal zone lymphoma after at least 2 prior treatment lines; approximately 7,460 new MZL cases occur annually in the U.S.

Research Methodology

The assessment uses 2025 as the base year, 2026 as the current year, historical reference years of 2022–2024, and a 2026–2034 forecast horizon. Mandatory supplied tables serve as the primary quantitative source for country and therapy values: USD 31,672.12 million is used as the 2026 regional country-level total and USD 57,499.93 million as the corresponding 2034 projection, while the separately supplied therapy table totals USD 31,705.09 million in 2026 and USD 58,059.76 million in 2034. These datasets are preserved independently because their totals differ by USD 32.97 million in 2026 and USD 559.83 million in 2034. Shares are calculated directly from the relevant supplied totals, while external regulatory and corporate disclosures are used only for qualitative industry context, commercialization indicators, and recent developments; unsupported segment allocations are not estimated.